Eli Lilly (LLY) expects to start selling its weight-loss drug tirzepatide, branded as Mounjaro, in Hong Kong as early as the end of this year after the company gained the Hong Kong government approval to sell the drug in a device called Kwikpen for both long-term weight management and type 2 diabetes,

The drugmaker has received approval from the Hong Kong government to sell its tirzepatide injections — branded as Mounjaro — in a device called Kwikpen for both long-term weight management and type 2 diabetes, Eli Lilly told Bloomberg in a statement.

Eli Lilly & Co. (NYSE:LLY) plans to start selling its popular weight-loss medication, Mounjaro, in Hong Kong by the end of this year, potentially becoming the first drug of its kind available in the broader China region,

A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around how the FDA maintains its list of drug shortages.

Eli Lilly to Introduce Mounjaro Weight-Loss Drug in Hong Kong by Year-End Global pharmaceutical giant Eli Lilly is gearing up to launch its weight-loss drug, Mounjaro, in Hong Kong by the end of this

Eli Lilly & Co. expects to start selling its highly popular weight-loss drug in Hong Kong as early as the end of this year, potentially making it the first of its kind to become available in the China region.

Eli Lilly (NYSE:LLY) received approval from the Hong Kong government to launch its weight-loss drug—Mounjaro, with sales expected to begin as early as year-end, Bloomberg reported. The company got approval to sell its tirzepatide injections—branded as Mounjaro—in a device called Kwikpen.